App-Quantinova.ai

Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations

F. Niccolini - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Management of fragility fractures in Parkinson’s Disease (PD)

G. Alg - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Mild cognitive impairment in newly diagnosed Parkinson’s disease: a three year follow up

R. Lawson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Modulation of executive motor network after neurofeedback training in Parkinson’s disease

N. Smulders - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Motor imagery increases imitation of hand movements in Parkinson’s disease

J. Bek - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Motor performance measured with the UPDRS in PD patientswith varying degrees of smell loss

c. cox - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Motor resonance in Parkinson’s disease: Effects of observed actions on behaviour

E. Poliakoff - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review

J. Fernandez Bonfante - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Non-motor symptom burden is associated with thalamic atrophy in Parkinson’s disease

F. Niccolini - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Non-motor symptoms in a cross section of PD patients with varying degrees of smell loss

c. cox - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients

M. Qamar - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Ioflupane

NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy

B. Balint - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Pain and Parkinson’s disease

H. Wilson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Parkinson’s disease phenotype across different ethnic groups: Comparison of non-motor symptoms in patients living in the United Kingdom and Mexico

A. Sauerbier - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Phosphodiesterases and striatal pathways in Parkinson’s disease

H. Wilson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Rolipram

Post-movement beta rebound inhibits future movement

E. Rhodes - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

G. Pagano - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Predict cognitive decline with non-clinical markers in Parkinson’s disease

T. Yousaf - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Pro-saccades predict decline in attention over 18months in newly diagnosed Parkinson’s disease

S. Stuart - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Prospective Analysis of Morphological Markers of Development of Impulsive Compulsive Behaviors in De Novo Parkinson’s Disease

L. Ricciardi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts